File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer

TitleHypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer
Authors
Keywordshypoxia
metabolism
metabolic reprogramming
drug resistance
TKIs
Issue Date2021
PublisherMDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cells
Citation
Cells, 2021, v. 10 n. 7, p. article no. 1715 How to Cite?
AbstractHypoxia, low oxygen (O2) level, is a hallmark of solid cancers, especially hepatocellular carcinoma (HCC), one of the most common and fatal cancers worldwide. Hypoxia contributes to drug resistance in cancer through various molecular mechanisms. In this review, we particularly focus on the roles of hypoxia-inducible factor (HIF)-mediated metabolic reprogramming in drug resistance in HCC. Combination therapies targeting hypoxia-induced metabolic enzymes to overcome drug resistance will also be summarized. Acquisition of drug resistance is the major cause of unsatisfactory clinical outcomes of existing HCC treatments. Extra efforts to identify novel mechanisms to combat refractory hypoxic HCC are warranted for the development of more effective treatment regimens for HCC patients.
Persistent Identifierhttp://hdl.handle.net/10722/305938
ISSN
2023 Impact Factor: 5.1
2023 SCImago Journal Rankings: 1.547
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorBAO, MHR-
dc.contributor.authorWong, CCL-
dc.date.accessioned2021-10-20T10:16:29Z-
dc.date.available2021-10-20T10:16:29Z-
dc.date.issued2021-
dc.identifier.citationCells, 2021, v. 10 n. 7, p. article no. 1715-
dc.identifier.issn2073-4409-
dc.identifier.urihttp://hdl.handle.net/10722/305938-
dc.description.abstractHypoxia, low oxygen (O2) level, is a hallmark of solid cancers, especially hepatocellular carcinoma (HCC), one of the most common and fatal cancers worldwide. Hypoxia contributes to drug resistance in cancer through various molecular mechanisms. In this review, we particularly focus on the roles of hypoxia-inducible factor (HIF)-mediated metabolic reprogramming in drug resistance in HCC. Combination therapies targeting hypoxia-induced metabolic enzymes to overcome drug resistance will also be summarized. Acquisition of drug resistance is the major cause of unsatisfactory clinical outcomes of existing HCC treatments. Extra efforts to identify novel mechanisms to combat refractory hypoxic HCC are warranted for the development of more effective treatment regimens for HCC patients.-
dc.languageeng-
dc.publisherMDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cells-
dc.relation.ispartofCells-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjecthypoxia-
dc.subjectmetabolism-
dc.subjectmetabolic reprogramming-
dc.subjectdrug resistance-
dc.subjectTKIs-
dc.titleHypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer-
dc.typeArticle-
dc.identifier.emailWong, CCL: carmencl@pathology.hku.hk-
dc.identifier.authorityWong, CCL=rp01602-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/cells10071715-
dc.identifier.pmid34359884-
dc.identifier.pmcidPMC8304710-
dc.identifier.scopuseid_2-s2.0-85114071261-
dc.identifier.hkuros326984-
dc.identifier.volume10-
dc.identifier.issue7-
dc.identifier.spagearticle no. 1715-
dc.identifier.epagearticle no. 1715-
dc.identifier.isiWOS:000677344000001-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats